Tumor-associated antigen-presenting pathway via dendritic cell cross-presentation

The **tumor-associated antigen-presenting pathway via dendritic cell cross-presentation** is not a single molecule or therapeutic target, but rather a specialized **immunological process**. **Dendritic cells (DCs)** are professional antigen-presenting cells capable of taking up **exogenous antigens** (such as those released from tumor cells) and presenting them on **major histocompatibility complex (MHC) class I molecules** to **CD8+ cytotoxic T cells**[3][7][8]. This process, termed **cross-presentation**, is critical for initiating immune responses against tumors and pathogens, as well as for maintaining self-tolerance[3][2][7][8]. Two main mechanisms have been described: the **cytosolic pathway** (where antigens are transferred into the cytosol, degraded by the proteasome, and then loaded onto MHC I) and the **vacuolar pathway** (where antigens are processed and loaded onto MHC I in endosome compartments)[3][2][7]. Cross-presentation by dendritic cells is essential in **anti-tumor immunity**, as it allows the immune system to recognize and target cells presenting tumor-associated antigens that might otherwise evade direct immune detection[8][3][7]. However, the pathway itself does **not represent a single molecular target, receptor, or druggable entity**—it is a composite of cellular mechanisms and intracellular trafficking routes within dendritic cells[3][1][2][7][8]. Interfering with or enhancing this pathway can influence the effectiveness of cancer immunotherapies, but there is no canonical molecule or receptor named "Tumor-associated antigen-presenting pathway via dendritic cell cross-presentation." Accordingly: - The designation is **not a valid therapeutic target** but describes a crucial immune process. - Entries for interacting drugs, mechanisms of action, biomarkers, and safety concerns are **not applicable** to a pathway as opposed to a molecule or receptor.

Other names

Cross-presentation pathwayAntigen cross-presentationDendritic cell cross-presentation pathway